Multiple CGM Sensors May Be Used with Automated Insulin Delivery

Why It Matters

Higher automation uptime and longer sensor wear improve glycemic outcomes, reinforcing the importance of system integration over sensor brand. This evidence supports broader adoption of interchangeable AID components across the diabetes market.

Key Takeaways

• Instinct sensor raised TIR to 77% from 75% with Guardian 4.
• Automated mode usage climbed to 95.8% with Instinct sensor.
• Sensor wear time increased to 97.5% versus 90.5% previously.
• Auto‑bolus insulin doses rose, basal proportion fell with Instinct.
• Study covered 13,967 U.S. MiniMed 780G users.

Pulse Analysis

The MiniMed 780G hybrid closed‑loop system has long relied on Medtronic’s Guardian 4 sensor, but the recent FDA clearance to pair the pump with Abbott’s Instinct CGM expands clinicians’ toolkit. By allowing two industry‑leading sensors to drive the same algorithm, manufacturers signal confidence that the control logic, rather than the sensor brand, dictates outcomes. This regulatory step also reflects a broader trend toward modular diabetes platforms, where interchangeable components can accelerate adoption and reduce supply‑chain constraints for patients seeking automated insulin delivery.

The real‑world analysis presented at the International Conference on Advanced Technologies & Treatments for Diabetes examined nearly 14,000 U.S. users who logged at least 30 days on both sensors. Switching to Instinct nudged average time‑in‑range from 75.1 % to 77 %, while the proportion of time spent in automated mode rose from 89.5 % to 95.8 %. Sensor wear time also improved, reaching 97.5 % of days. These gains coincided with a shift toward more auto‑bolus insulin (16.5 U vs. 12.9 U) and a modest reduction in basal insulin share.

For providers, the data suggest that sensor selection can be secondary to maintaining high automation uptime, reinforcing the value of devices that encourage continuous wear. Patients benefit from fewer sensor changes and longer periods of closed‑loop control, which may translate into lower complication risk and improved quality of life. Industry analysts see the interoperability as a catalyst for competition, prompting other pump makers to pursue similar sensor‑agnostic approvals. As more data emerge, the balance between sensor accuracy and system robustness will shape the next generation of AID therapies.